Literature DB >> 27273809

Preparing a prescription drug monitoring program data set for research purposes.

Nicole O'Kane1, Sara E Hallvik1, Miguel Marino2,3, Joshua Van Otterloo4, Christi Hildebran1, Gillian Leichtling1, Richard A Deyo2,5,6,7.   

Abstract

PURPOSE: To develop a complete and consistent prescription drug monitoring program (PDMP) data set for use by drug safety researchers in evaluating patterns of high-risk use and potential abuse of scheduled drugs.
METHODS: Using publically available data references from the US Food and Drug Administration and the Centers for Disease Control and Prevention, we developed a strategic methodology to assign drug categories based on pharmaceutical class for the majority of prescriptions in the PDMP data set. We augmented data elements required to calculate morphine milligram equivalents and assigned duration of action (short-acting or long acting) properties for a majority of opioids in the data set.
RESULTS: About 10% of prescriptions in the PDMP data set did not have a vendor-assigned drug category, and 20% of opioid prescriptions were missing data needed to calculate risk metrics. Using inclusive methods, 19 133 167 (>99.9%) of prescriptions in the PDMP data set were assigned a drug category. For the opioid category, augmenting data elements resulted in 10 760 669 (99.8%) having required values to calculate morphine milligram equivalents and evaluate duration of action properties.
CONCLUSIONS: Drug safety researchers who require a complete and consistent PDMP data set can use the methods described here to ensure that prescriptions of interest are assigned consistent drug categories and complete opioid risk variable values.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  data sources; diversion measurement; metrics; pharmacoepidemiology; prescription drug abuse; prescription drug monitoring program; prescription opioid

Mesh:

Substances:

Year:  2016        PMID: 27273809      PMCID: PMC5089899          DOI: 10.1002/pds.4039

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  3 in total

Review 1.  What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose.

Authors:  Tamara M Haegerich; Leonard J Paulozzi; Brian J Manns; Christopher M Jones
Journal:  Drug Alcohol Depend       Date:  2014-10-14       Impact factor: 4.492

2.  Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy.

Authors:  Matthew Miller; Catherine W Barber; Sarah Leatherman; Jennifer Fonda; John A Hermos; Kelly Cho; David R Gagnon
Journal:  JAMA Intern Med       Date:  2015-04       Impact factor: 21.873

3.  Opioid prescriptions for chronic pain and overdose: a cohort study.

Authors:  Kate M Dunn; Kathleen W Saunders; Carolyn M Rutter; Caleb J Banta-Green; Joseph O Merrill; Mark D Sullivan; Constance M Weisner; Michael J Silverberg; Cynthia I Campbell; Bruce M Psaty; Michael Von Korff
Journal:  Ann Intern Med       Date:  2010-01-19       Impact factor: 25.391

  3 in total
  6 in total

1.  Association Between Initial Opioid Prescribing Patterns and Subsequent Long-Term Use Among Opioid-Naïve Patients: A Statewide Retrospective Cohort Study.

Authors:  Richard A Deyo; Sara E Hallvik; Christi Hildebran; Miguel Marino; Eve Dexter; Jessica M Irvine; Nicole O'Kane; Joshua Van Otterloo; Dagan A Wright; Gillian Leichtling; Lisa M Millet
Journal:  J Gen Intern Med       Date:  2016-08-02       Impact factor: 5.128

2.  Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers.

Authors:  Richard A Deyo; Sara E Hallvik; Christi Hildebran; Miguel Marino; Rachel Springer; Jessica M Irvine; Nicole O'Kane; Joshua Van Otterloo; Dagan A Wright; Gillian Leichtling; Lisa M Millet; Jody Carson; Wayne Wakeland; Dennis McCarty
Journal:  J Pain       Date:  2017-10-18       Impact factor: 5.820

3.  Opioid-Prescribing Continuity and Risky Opioid Prescriptions.

Authors:  Sara E Hallvik; Peter Geissert; Wayne Wakeland; Christi Hildebran; Jody Carson; Nicole O'Kane; Richard A Deyo
Journal:  Ann Fam Med       Date:  2018-09       Impact factor: 5.166

4.  Use of prescription opioids before and after an operation for chronic pain (lumbar fusion surgery).

Authors:  Richard A Deyo; Sara E Hallvik; Christi Hildebran; Miguel Marino; Nicole O'Kane; Jody Carson; Joshua Van Otterloo; Dagan A Wright; Lisa M Millet; Wayne Wakeland
Journal:  Pain       Date:  2018-06       Impact factor: 7.926

5.  Doctor hopping and doctor shopping for prescription opioids associated with increased odds of high-risk use.

Authors:  Sean G Young; Corey J Hayes; Jonathan Aram; Mark A Tait
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-06-05       Impact factor: 2.890

6.  Record Linkage Approaches Using Prescription Drug Monitoring Program and Mortality Data for Public Health Analyses and Epidemiologic Studies.

Authors:  Sarah Nechuta; Sutapa Mukhopadhyay; Shanthi Krishnaswami; Molly Golladay; Melissa McPheeters
Journal:  Epidemiology       Date:  2020-01       Impact factor: 4.822

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.